Ask AI
ProCE Banner Activity

SACHI: Phase III Trial of Savolitinib + Osimertinib vs Chemotherapy in EGFR-Mutant, MET-Amplified Advanced NSCLC After an EGFR TKI

Conference Coverage
Slideset

In the randomized phase III SACHI trial, savolitinib plus osimertinib led to clinically meaningful improvements in PFS vs traditional platinum-based chemotherapy in patients with EGFR-mutant, MET-amplified advanced NSCLC following 1L EGFR TKI failure.

Released: June 03, 2025

Expiration: December 02, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar